Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence
Theodore M. Brasky(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Louise A. Brinton(National Cancer Institute), Michael L. Pearl(Stony Brook University), Kay J. Park(Memorial Sloan Kettering Cancer Center), Ashley S. Felix(Wake Forest University), Premal H. Thaker(Washington University in St. Louis), John F. Boggess(University of Kentucky), Richard G. Moore(University of Rochester Medical Center), Joan L. Walker(Cornell University), Saketh R. Guntupalli(University of Colorado Cancer Center), Shashikant Lele(Memorial Sloan Kettering Cancer Center), David G. Mutch(Cancer Research Center), David E. Cohn(The Ohio State University), Christa Nagel(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Shamshad Ali(Roswell Park Comprehensive Cancer Center), D. Scott McMeekin(University of Oklahoma), Levi S. Downs(University of Toronto), William T. Creasman(Medical University of South Carolina), Olga B. Ioffe(University of Maryland, Baltimore)
Cited by 57
Related Papers
Integrated genomic analyses of ovarian carcinoma
|Nature|2011|8.2k
Intraepithelial CD8 <sup>+</sup> tumor-infiltrating lymphocytes and a high CD8 <sup>+</sup> /regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
|Proceedings of the National Academy of Sciences|2005|2.4k